{"id":"preventive-administration-of-rapaflo","safety":{"commonSideEffects":[{"rate":"28","effect":"Retrograde ejaculation"},{"rate":"3-5","effect":"Dizziness"},{"rate":"3-4","effect":"Diarrhea"},{"rate":"2-3","effect":"Orthostatic hypotension"},{"rate":"2","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Silodosin selectively blocks alpha-1A adrenergic receptors located in the prostate and bladder outlet, reducing smooth muscle tone and urinary obstruction. This mechanism alleviates lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). The preventive administration approach in this trial likely aims to evaluate whether early treatment can delay symptom progression or disease advancement.","oneSentence":"Rapaflo (silodosin) is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:05.591Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms — preventive/early intervention"}]},"trialDetails":[{"nctId":"NCT02220829","phase":"PHASE3","title":"Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-06","conditions":"Urinary Problems, Prostate Cancer","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapaflo","Silodosin"],"phase":"phase_3","status":"active","brandName":"Preventive administration of Rapaflo","genericName":"Preventive administration of Rapaflo","companyName":"Sir Mortimer B. Davis - Jewish General Hospital","companyId":"sir-mortimer-b-davis-jewish-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rapaflo (silodosin) is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms — preventive/early intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}